Molecular mechanism of CCDC106 regulating the p53-Mdm2/MdmX signaling axis-Reference-Cited by-同舟云学术

Molecular mechanism of CCDC106 regulating the p53-Mdm2/MdmX signaling axis

Published:2023-12-11 Issue:1 Volume:13 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Zhou Ting,Ke Zhiqiang,Ma Qianqian,Xiang Jiani,Gao Meng,Huang Yongqi,Cheng Xiyao^ORCID,Su Zhengding^ORCID

Abstract

AbstractThe tumor suppressor p53 (p53) is regulated by murine double minute 2 (Mdm2) and its homologous MdmX in maintaining the basal level of p53. Overexpressed Mdm2/MdmX inhibits cellular p53 activity, which is highly relevant to cancer occurrence. Coiled-coil domain-containing protein 106 (CCDC106) has been identified as a p53-interacting partner. However, the molecular mechanism of the p53/Mdm2/MdmX/CCDC106 interactions is still elusive. Here, we show that CCDC106 functions as a signaling regulator of the p53-Mdm2/MdmX axis. We identified that CCDC106 directly interacts with the p53 transactivation domain by competing with Mdm2 and MdmX. CCDC106 overexpression downregulates the cellular level of p53 and Mdm2/MdmX, and decreased p53 reversibly downregulates the cellular level of CCDC106. Our work provides a molecular mechanism by which CCDC106 regulates the cellular levels of p53 and Mdm2/MdmX.

Funder

Hubei Province Education Office Fund Project

Guangxi University Initialtives

Natural Science Foundation of China

Hubei University of Technology

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

https://www.nature.com/articles/s41598-023-47808-z.pdf

Reference23 articles.

1. Zhou, J. et al. Identification and characterization of the novel protein CCDC106 that interacts with p53 and promotes its degradation. FEBS Lett. 584, 1085–1090. https://doi.org/10.1016/j.febslet.2010.02.031 (2010).

2. Zhao, N. et al. CCDC106 promotes the proliferation and invasion of ovarian cancer cells by suppressing p21 transcription through a p53-independent pathway. Bioengineered 13, 10956–10972. https://doi.org/10.1080/21655979.2022.2066759 (2022).

3. Ning, Y. et al. CK2-mediated CCDC106 phosphorylation is required for p53 degradation in cancer progression. J. Exp. Clin. Cancer Res. 38, 131. https://doi.org/10.1186/s13046-019-1137-8 (2019).

4. Zhang, X. et al. CCDC106 promotes non-small cell lung cancer cell proliferation. Oncotarget 8, 26662–26670. https://doi.org/10.18632/oncotarget.15792 (2017).

5. Duffy, M. J., Synnott, N. C. & Crown, J. Mutant p53 as a target for cancer treatment. Eur. J. Cancer 83, 258–265. https://doi.org/10.1016/j.ejca.2017.06.023 (2017).